Walker R
University of Surrey, School of Biological Sciences, Guildford, Surrey, United Kingdom.
Regul Toxicol Pharmacol. 1999 Oct;30(2 Pt 2):S119-21. doi: 10.1006/rtph.1999.1337.
Monosodium glutamate (MSG) has been allocated an "ADI not specified" by the JECFA, which indicates that no toxicological concerns arise associated with its use as a food additive in accordance with good manufacturing practice (GMP) and for that reason it is not necessary to allocate a numerical ADI. The question in this case, then, is not whether excursions above a numerical ADI might occur but whether high peak intakes might arise which could invalidate the assumption of absence of hazard. Two major issues have arisen in relation to high intakes of MSG: (1) What is the significance of neural damage (focal necrosis in the hypothalamus) seen following high parenteral or intragastric doses of MSG to neonatal animals and is this a particular risk for children? (2) What is the role of MSG in "Chinese Restaurant Syndrome" (flushing, tightness of the chest, difficulty in breathing, etc.) following consumption of Chinese foods? In relation to the first issue, human studies have been crucial in resolving the question. The threshold blood levels associated with neuronal damage in the mouse (most sensitive species) are 100-130 mumol/dl in neonates rising to > 630 mumol/dl in adult animals. In humans, plasma levels of this magnitude have not been recorded even after bolus doses of 150 mg/kg body wt (ca. 10 g for an adult). Additionally, studies in infants have confirmed that the human baby can metabolize glutamate as effectively as adults. It is concluded that blood levels of glutamate + aspartate do not rise significantly even after abuse doses and babies are no more at risk than adults. Intake levels associated with the use of MSG as a food additive and natural levels of glutamic acid in foods therefore do not raise toxicological concerns even at high peak levels of intake. It is not envisaged that use of MSG according to GMP requires the allocation of a numerical ADI. With regard to the second issue, controlled double-blind crossover studies have failed to establish a relationship between Chinese Restaurant Syndrome and ingestion of MSG, even in individuals reportedly sensitive to Chinese meals, and MSG did not provoke bronchoconstriction in asthmatics. Thus, high usage of MSG in ethnic cuisines does not represent a situation in which intakes might achieve unsafe levels, even among individuals claiming idiosyncratic intolerance of such foods. In the light of the toxicological studies, the human metabolic studies in neonates and adults, and the physiological and nutritional role of glutamic acid and the fact that food additive use does not markedly increase the total dietary burden, no foreseeable circumstances arise in which intakes would be such as to invalidate the appropriateness of allocating an ADI not specified to MSG.
食品添加剂联合专家委员会(JECFA)已将味精(MSG)的每日允许摄入量(ADI)列为“未规定”,这表明按照良好生产规范(GMP)将其用作食品添加剂不会产生毒理学问题,因此无需指定具体的ADI数值。那么,在这种情况下,问题不在于是否会超过某个具体的ADI数值,而在于是否会出现高剂量峰值摄入,从而使不存在危害的假设无效。关于高剂量摄入味精出现了两个主要问题:(1)对新生动物进行高剂量的肠胃外或胃内注射味精后,观察到的神经损伤(下丘脑局灶性坏死)有何意义,这对儿童来说是否是一种特殊风险?(2)食用中餐后出现的“中餐综合征”(脸红、胸闷、呼吸困难等)中,味精起到了什么作用?关于第一个问题,人体研究对于解决该问题至关重要。与小鼠(最敏感的物种)神经元损伤相关的血液阈值水平,新生小鼠为100 - 130 μmol/dl,成年动物则升至> 630 μmol/dl。在人类中,即使给予150 mg/kg体重的大剂量注射(成人约10 g)后,也未记录到如此高的血浆水平。此外,对婴儿进行的研究证实,人类婴儿代谢谷氨酸的能力与成年人一样有效。得出的结论是,即使在滥用剂量后,谷氨酸+天冬氨酸的血液水平也不会显著升高,婴儿与成年人面临的风险并无差异。因此,即使在高剂量峰值摄入的情况下,作为食品添加剂使用味精的摄入水平以及食物中谷氨酸的天然含量也不会引发毒理学问题。按照GMP使用味精,预计无需指定具体的ADI数值。关于第二个问题,对照双盲交叉研究未能证实中餐综合征与摄入味精之间存在关联,即使在据报道对中餐敏感的个体中也是如此,并且味精不会诱发哮喘患者的支气管收缩。因此,即使在声称对这类食物存在特异不耐受的个体中,民族菜肴中大量使用味精也并不意味着摄入量会达到不安全水平情况。鉴于毒理学研究、针对新生儿和成年人的人体代谢研究、谷氨酸的生理和营养作用以及食品添加剂的使用不会显著增加总膳食负担这一事实,在可预见的情况下,摄入量都不会使将未规定的ADI指定给味精变得不合理无效。